As interstitial PDT applied to GBM is already suggested in clinical practice, our current goal is to revise the existing practice by exploiting NRP-1-targeting nanoparticles, i.e., to propose an optimized irradiation scheme by taking into account inflammation and vascular responses. This evidence concerns the gene NRP1 and glioblastoma.